Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005

Anan, Keisei; Fukui, Naohito; Kinoshita, Takayuki; Inomata, Takayuki; Niikura, Naoki; Kawai, Masaaki; Hayashi, Naoki; Tsugawa, Kouichiro; Aogi, Kenjiro; Ishida, Toru; Masuoka, Hideji; Masuda, Sinobu; Iijima, Kotaro; Nakamura, Seigo; Tokuda, Yutaka

doi:10.1007/s12282-015-0645-4

Cited by 6 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Japanese Breast Cancer Society (JBCS) Registry reported that the frequencies of stage 0, I, II, III and IV were 9.5%, 38.2%, 41.0%, 8.5% and 2.9%, respectively 11 . In addition, the JBCS Registry reported that the proportions of ER and PgR positivity were 75.7% and 62.3% among those registered in 2005, respectively 11 .…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the JBCS Registry reported that the proportions of ER and PgR positivity were 75.7% and 62.3% among those registered in 2005, respectively 11 . Furthermore, with respect to histological type of breast cancer, the JBCS Registry reported proportions of 82.9%, 8.2% and 8.9% for invasive carcinoma, non-invasive ductal carcinoma and remaining types (including non-invasive lobular carcinoma and special and other types), respectively, among breast cancer patients registered in 2004 20 .…”

Section: Discussionmentioning

confidence: 99%

“…The JBCS Registry further demonstrated that more advanced stage was associated with poorer prognosis in breast cancer patients after a median follow-up period of 60.0 months 11 . A negative ER status tended to be associated with poorer prognosis, compared with a positive ER status, although prognosis was compared with respect to both ER and human epidermal growth factor receptor 2 statuses 11 .…”

Section: Discussionmentioning

confidence: 99%

“…A negative ER status tended to be associated with poorer prognosis, compared with a positive ER status, although prognosis was compared with respect to both ER and human epidermal growth factor receptor 2 statuses 11 . PgR negativity also tended to be associated with poorer prognosis, compared with PgR positivity, although this comparison was conducted only in ER-positive cases 11 . The effectiveness of endocrine therapy may explain better prognosis in ER- or PgR-positive cases compared with the respective negative cases 22 .…”

Section: Discussionmentioning

confidence: 99%

“…According to the latest Japanese National Vital Statistics, 13,240 annual deaths are due to breast cancer in females, and breast cancer is the fifth leading cause of cancer-related death in Japanese females 10 . Cancer stage and other clinical factors at diagnosis predict prognosis in breast cancer patients 11 . Recently, interest has increased in hormone receptors such as estrogen receptor (ER) and progesterone receptor (PgR) with regard to the therapeutic strategies and prognostic assessment of breast cancer 12 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

Nakamura

Okada

Ukawa

et al. 2017

Journal of Epidemiology

View full text Add to dashboard Cite

BackgroundBreast cancer is currently the most common type of cancer in Japanese females. Unlike most other types of cancer, breast cancer develops more frequently in middle-aged females than in elderly females.MethodsOf all Japanese female breast cancer patients aged ≥20 years whom the BioBank Japan Project originally enrolled between 2003 and 2008, 2034 were registered within 90 days after their diagnosis. We described the lifestyle and clinical characteristics of these patients at study entry. Furthermore, we examined the effect of these characteristics on all-cause mortality.ResultsIn the female patients registered within 90 days after diagnosis, the frequency of stage 0 or unclassified, stage I, II, III and IV were 11.4%, 47.9%, 37.0%, 2.9% and 0.8%, respectively. The proportion of histological types was 12.9% for non-invasive carcinoma (ductal carcinoma and lobular carcinoma), 81.0% for invasive carcinoma (papillotubular carcinoma, solid tubular carcinoma, scirrhous carcinoma and special types), 0.2% for Paget's diseases and 5.8% for others. Those positive for the estrogen and progesterone receptors accounted for 75.8% and 62.1% of all patients, respectively. Among 1860 female participants registered within 90 days, 218 participants died during 144,54 person-years of follow-up. More advanced stage, elevation of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels and absence of the estrogen receptor at study entry were crudely associated with an increased risk of all-cause mortality after adjustment for age.ConclusionsThis study showed the association of several clinical characteristics with all-cause mortality in female breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

Nakamura

Okada

Ukawa

et al. 2017

Journal of Epidemiology

View full text Add to dashboard Cite

show abstract

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

Takahashi

Masuda

Nishimura³

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐label, single‐arm, Japanese phase 2 study was conducted to investigate the efficacy and safety of palbociclib plus letrozole as first‐line treatment in 42 postmenopausal patients with estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. The probability of progression‐free survival originally reported at 1 year was 75.0% (90% confidence interval, 61.3‐84.4), but median progression‐free survival was not attained at the primary analysis. In this report, updated efficacy and safety results with a longer follow‐up period are presented. The median duration of treatment in the updated analysis was 33.0 months (range, 1.8‐49.2). The probability of progression‐free survival at 1 year was 75.6% (90% confidence interval, 62.4‐84.7). Median progression‐free survival was 35.7 months (95% confidence interval, 21.7‐46.7). Objective response rate and disease control rate were 47.6% (95% confidence interval, 32.0‐63.6) and 85.7% (95% confidence interval, 71.5‐94.6), respectively. Common treatment‐related adverse events (all grades; grade 3/4) were neutropenia (100%; 93%), leukopenia (83%; 60%), and stomatitis (76%; 0%). Treatment‐related febrile neutropenia was reported in one patient. In general, no clinically meaningful deterioration in health‐related quality of life was observed. Palbociclib plus letrozole remained effective and tolerable in Japanese postmenopausal patients with estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer in this updated analysis.

show abstract

Morphological and Molecular Approaches to Breast Cancer Risk Assessment

Masuda

2018

Pathology of Female Cancers

View full text Add to dashboard Cite

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005

Cited by 6 publications

References 2 publications

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

Morphological and Molecular Approaches to Breast Cancer Risk Assessment

Contact Info

Product

Resources

About